In future, targeted cancer therapies using molecules, such as BRAF inhibitors, and cytotoxic T-lymphocyte-associated protein, programmed cell death protein 1 and programmed death-ligand 1 antibodies (17–20), may be effective options for treating cases of advanced malignant melanoma, including those originating in the trachea. This evidence concerns the gene PDCD1 and melanoma.